REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

22 Oct 2023 14:59:00 By Nasdaq GlobeNewswire

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

21 Oct 2023 08:48:15 By Nasdaq GlobeNewswire

Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

20 Oct 2023 17:00:37 By Nasdaq GlobeNewswire

Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

18 Oct 2023 09:30:00 By Nasdaq GlobeNewswire

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

18 Oct 2023 09:00:00 By Nasdaq GlobeNewswire

Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

15 Oct 2023 18:05:23 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

13 Oct 2023 09:48:32 By NetDania Notify

EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA

05 Oct 2023 09:43:00 By Nasdaq GlobeNewswire

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

29 Sep 2023 08:30:12 By Nasdaq GlobeNewswire

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

28 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

26 Sep 2023 01:29:00 By Nasdaq GlobeNewswire

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

25 Sep 2023 08:34:45 By Nasdaq GlobeNewswire

Regeneron Provides Update on Planned Chief Financial Officer Transition

08 Sep 2023 16:46:00 By Nasdaq GlobeNewswire

Regeneron Announces Updates to Board of Directors

08 Sep 2023 16:45:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

23 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention

22 Aug 2023 14:15:41 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

22 Aug 2023 10:15:09 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

21 Aug 2023 12:37:50 By NetDania Notify

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

18 Aug 2023 18:35:00 By Nasdaq GlobeNewswire